Seeking Alpha·Oct 29, 2026
West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call TranscriptWest Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
West Pharmaceutical's revenue re-accelerated to $874.5M in 2026Q3, up 8.7% year over year after 13.8% and 21.0% growth in the two prior quarters, and gross margin expanded from 32.9% in 2024Q2 to 39.7%, suggesting the shift toward proprietary high-value products is driving durable operating leverage.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue grew 8.7% year over year to $874.5M in 2026Q3 while gross margin reached 39.7% and operating margin reached 30.6%, though the reported margin expansion appears heavily concentrated in the most recent quarter and warrants monitoring for sustainability.
West Pharmaceutical Services has a consistent track record of exceeding earnings expectations, indicating strong financial performance.
The company is a leading global manufacturer of advanced containment and delivery systems for injectable medicines, positioning it as a trusted industry player.
West specializes in designing and producing high-quality, technologically advanced packaging and delivery systems for pharmaceuticals, driving growth in the sector.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $2.66+20.9% vs $2.20 | $875M+5.7% vs $827M |
Q3 2026 Jul 23, 2026 | $2.37+13.9% vs $2.08 | $872M+3.8% vs $840M |
Q2 2026 Apr 23, 2026 | $2.13+26.8% vs $1.68 | $845M+8.3% vs $780M |
Q1 2026 Feb 12, 2026 | $2.04+11.5% vs $1.83 | $805M+1.3% vs $795M |
West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $1.96 per share a year ago.
Benchmark WST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for West Pharmaceutical Services, Inc. (WST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $399.81 | $28.14B | 44.31 | 6.26% | 18.81% | 21.08% | 0.21% | |
| $142.50 | $9.09B | 34.21 | 5.42% | 6.69% | 9.97% | 1.27% | |
| $15.47 | $10.46B | 31.24 | -3.41% | 5.08% | 5.96% | — | |
| $44.87 | $20.75B | 19.20 | 56.61% | 4.55% | 9.27% | 5.74% | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $276.22 | $664.92B | 42.02 | 6.05% | 16.2% | 19.55% | 1.85% |
West Pharmaceutical Services, Inc. (WST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
West Pharmaceutical Services, Inc. (WST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 26, 2026·SEC
Jul 23, 2026·SEC
Get notified when WST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
West Pharmaceutical Services, Inc. (WST) stock FAQ — growth, dividends, profitability & financials explained
West Pharmaceutical Services, Inc. (WST) reported $3.40B in revenue over the trailing twelve months. Revenue was $3.07B in fiscal year 2025. That is 570% more than the $458.8M of fiscal year 1996.
West Pharmaceutical Services, Inc. (WST) grew revenue by 12.6% over the trailing twelve months, compared with the twelve months before.
Yes. West Pharmaceutical Services, Inc. (WST) earned $638.9M in net income over the trailing twelve months (a 18.8% net margin).
Yes. West Pharmaceutical Services, Inc. (WST) pays a dividend that yields 0.21% at the current price, a small yield.
West Pharmaceutical Services, Inc. (WST) had a return on equity (ROE) of 21.1% over the trailing twelve months. That is well above the market's typical 10-15%.
West Pharmaceutical Services, Inc. (WST) generated $453.4M in free cash flow over the trailing twelve months.
